तुलना करने के लिए मीट्रिक्स | GENIG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGENIGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.3x | −0.8x | −0.5x | |
PEG अनुपात | −0.07 | −0.01 | 0.00 | |
क़ीमत/बुक | 60.7x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.4x | 0.5x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 74.4% | 58.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 32.4% | 10.2% | अनलॉक करें |
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.